The need for precise dose information of sodium selenite in the SIC study and rectification of GPx-3 plasma concentration [12]

Critical Care Medicine

Volumn 36, Issue 2, 2008, Pages 657-

  Angstwurm, Matthias ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE PEROXIDASE; SELENIUM; SODIUM SELENITE;

CONTINUOUS INFUSION; DRUG BLOOD LEVEL; DRUG MEGADOSE; ENZYME ACTIVITY; HUMAN; LETTER; OXIDATIVE STRESS; PRIORITY JOURNAL; TREATMENT DURATION;

EID: 38549158917     PISSN: 00903493     EISSN: None     Source Type: Journal    
DOI: 10.1097/CCM.0b013e318162a1fd     Document Type: Letter

References (4)

1. Angstwurm MW, Engelmann L, Zimmermann T, et al: Selenium in Intensive Care (SIC): Results of a prospective randomized, placebo-controlled, multiple-center study in patients with severe systemic inflammatory response syndrome, sepsis, and septic shock. Crit Care Med 2007, 35:118-126
2. Mishra M, Baines S, Perry E, et al: Effect of selenium supplementation on biochemical markers and outcome in critically ill patients. Clin Nutr 2007; 26:41-50
3. Forceville X, Laviolle B, Annane D, et al: Effects of high doses of selenium, as sodium selenite, in septic shock: A placebo-controlled, randomized, double-blind, phase II study. Crit Care 2007; 11:R73
4. Angstwurm MW, Schottdorf J, Schopohl J, et al: Selenium replacement in patients with severe systemic inflammatory response syndrome improves clinical outcome. Crit Care Med 1999; 27:1807-1813